Document is current
Any future updates will be listed below
-
Authors
Placek, Katerina https://orcid.org/0000-0002-0832-6684
Benatar, Michael
Wuu, Joanne
Rampersaud, Evadnie
Hennessy, Laura
Van Deerlin, Vivianna M
Grossman, Murray
Irwin, David J
Elman, Lauren
McCluskey, Leo
Quinn, Colin
Granit, Volkan
Statland, Jeffrey M
Burns, Ted M
Ravits, John
Swenson, Andrea
Katz, Jon
Pioro, Erik P
Jackson, Carlayne
Caress, James
So, Yuen
Maiser, Samuel
Walk, David
Lee, Edward B
Trojanowski, John Q
Cook, Philip
Gee, James
Sha, Jin
Naj, Adam C
Rademakers, Rosa https://orcid.org/0000-0002-4049-0863
,
Chen, Wenan
Wu, Gang
Paul Taylor, J
McMillan, Corey T https://orcid.org/0000-0002-7581-6405
-
Funding
Funding for this research was provided by:
The CReATe Consortium (U54NS092091)
National Institutes of Health (NS106754)
National Institutes of Health (AG017586)
National Institutes of Health (NS092091)
National Institutes of Health (AG054060)
ALS Association (17‐LGCA‐331)
ALS Association (16‐TACL‐242)
- License Information
-
More Information
Article History
Received: 24 April 2020
Revised: 27 October 2020
Accepted: 30 October 2020
First Online: 3 December 2020
Conflict of interest
: The following authors declare the following conflicts of interest: C.T.M. receives financial support from Biogen and has provided consulting for Axon Advisors. M.B. reports grants from National Institutes of Health, the ALS Association, the Muscular Dystrophy Association, the Centers for Disease Control and Prevention, the Department of Defense, and Target ALS during the conduct of the study; personal fees from Mitsubishi Tanabe Pharma, AveXis, Prilenia, Genentech, and Roche outside the submitted work. In addition, M.B. has a provisional patent entitled “Determining Onset of Amyotrophic Lateral Sclerosis” and serves as a site investigator on clinical trials funded by Biogen and Orphazyme. All other authors declare no competing interests.
